Two clinical cases of acute and severe toxicity after bleomycin and methotrexate administration are described. In both cases toxicity became evident 2 to 3 days after chemotherapeutic treatment and consisted of ulceronecrotic mucositis, leuko- and thrombocytopenia and hypotension; one patient died 13 days after. Toxicity is quite unexpected in relation to the drug dosages and time of onset. Some pathogenetic hypotheses are discussed.
Get full access to this article
View all access options for this article.
References
1.
AdrianR.M.HoodA.F.SkarinA.T.: Mucocutaneous reactions to antineoplastic agents.CA, 30: 143–157, 1980.
2.
BarrancoS.C.LuceJ.K.RomsdahlM.M.HumphreyR.M.: Bleomycin as a possible synchronizing agent for human tumor cells in vivo.Cancer Res., 33: 882–887, 1973.
3.
BlumR.H.CarterS.K.AgreK.: A clinical review of bleomycin - A new antineoplastic agent.Cancer, 31: 903–913, 1973.
4.
BonmassarE.: Immunochemioterapia.In: II Corso di aggiornamento in Oncologia Medica, Firenze, 1976, pp. 59–74, 1976.
5.
BoxerL.A.GreenbergM.S.BoxerG.J.StosselT.P.: Autoimmune neutropenia.N. Engl. J. Med., 293: 748–753, 1975.
6.
ClineM.J.OpelzG.SaxonA.FaheyJ.L.GoldeD.W.: Autoimmunepanleukopenia.N. Engl. J. Med., 295: 1489–1493, 1976.
7.
CreavenP.J.MihicE.: Tossicità clinica dei farmaci antitumorali: Possibilità di prevederla.Aggiornamenti in Oncologia Clinica, 4: 486–518, 1978.
8.
KirtlandH.H.III, MohlerD.N.HorwitzD.A.: Methyldopa inhibition of suppressor-lymphocyte function: A proposed cause of autoimmune hemolytic anemia.N. Engl. J. Med., 302: 825–832, 1980.
9.
KyleR.A.: Natural history of chronic idiopathic neutropenia.N. Engl. J. Med., 302: 908–909, 1980.
10.
LalezariP.JiangA.F.YegenL.SantorineauM.: Chronic autoimmune neutropenia due to anti-Na 2-antibody.N. Engl. J. Med., 293: 744–747, 1975.
LuporiniG.LabiancaR.FraschiniP.BerettaG.: Tossicità a distanza dei farmaci antitumorali.Argomenti di Oncologia, 1: 317–326, 1980.
13.
MonfardiniS.: Effetti collaterali a breve e lungo termine dei farmaci antitumorali.IV Corso di Aggiornamento in Oncologia Medica, vol. II, pp. 979; Genova, 1978.
14.
NesbitM.KrivitW.HeynR.SharpH.: Acute and chronic effects of methotrexate on hepatic, pulmonary, and skeletal systems.Cancer, 37: 1048–1058, 1976.
15.
ParkinsonD.R.JeryL.M.ShibataH.R.LewisM.G.CanoP.O.CapekA.MansellP.W.MarquisG.: Complications of cancer immunotherapy with levamisole.Lancet, 2: 1129–1132, 1977.
16.
PolakL.: Suppressor cells in different types of unresponsiveness to DNCB contact sensitivity in guinea pigs.Clin. Exp. Immunol., 19: 543, 1975.
17.
RossoR.SertoliM.R.BoccardoF.: Reclutamento e sincronizzazione cellulare quali fattori per la risposta alla terapia.IV Corso di Aggiornamento in Oncologia Clinica, vol. I, pp. 41, Genova, 1978.
18.
Van NoorloosA.A.B.PegelsH.G.Van OersR.H.J.SilberbuschJ.Feltkamp-VroomT.M.GoudsmitR.ZeijlemakerW.P.Von dem BorneA.E.G. Kr.MeliefC.J.M.: Proliferation of T-gamma-cells with killer cell activity in two patients with neutropenia and recurrent infections.N. Engl. J. Med., 302: 933–937, 1980.
19.
VogelC.L.LipscombD.L.SilvermanM.A.KernsA.L.MansellP.W.SugarbakerE.V.: Levamisole granulocytopenia in patients receiving an adjuvant chemoimmunotherapy program after surgery for breast carcinoma with axillary lymph node involvement.Cancer Treat. Rep., 62: 1587–1589, 1978.
20.
WhitcombM.E.SchwarzM.I.TormeyD.C.: Methotrexate pneumonitis: Case report and review of literature.Thorax, 27: 636–639, 1972.
21.
YagodaA.MukherjiB.YoungC.EtcubanasE.LamonteC.SmithJ.R.TanC.T.C.KrakoffI.H.: Bleomycin, an antitumor antibiotic.Ann. Intern. Med., 77: 861–870, 1977.
